Supplemental Tables S1-S11 from The Pan-Tumor Landscape of Gene Amplifications and Copy Number Amplification Ratio for Established and Emerging Clinical Targets

作者：Jessica Lee, Júlia C.F. Quintanilha, Kuei‐Ting Chen, Bernard Fendler, Candice Francheska B. Tambaoan, Ryon P. Graf, Nicole B. Odzer, Lajos Pusztai, Maryam B. Lustberg, Harshabad Singh, Matthew R. Strickland, Tess A. O’Meara, Sara M. Tolaney, Timothy A. Yap, Jeffrey S. Ross, Amaya Gascó Hernández, Brennan Decker, Richard S.P. Huang, Samuel J. Klempner, Ethan Sokol, Alexa B. Schrock · 年份：2026 · DOI：10.1158/1078-0432.32845470 · 研究领域：HER2/EGFR in Cancer Research、Breast Cancer Treatment Studies、Monoclonal and Polyclonal Antibodies Research

<p>Supplemental Table 1: Demographics and clinical characteristics of the ERBB2-amplified mBC cohort treated with first-line trastuzumab-based regimens Supplemental Table 2: Demographics and clinical characteristics of the ERBB2-amplified mBC cohort treated with T-DXd Supplemental Table 3: Demographics and clinical characteristics of the ERBB2-amplified aGE cohort treated with first-line trastuzumab-based regimens Supplemental Table 4: Demographics and clinical characteristics of the ERBB2-amplified CRC cohort treated with trastuzumab Supplemental Table 5: ERBB2 NGS and HER2 IHC/FISH concordance for 3,650 mBC patients Supplemental Table 6: Demographics and clinical characteristics of the HER2+ mBC cohort treated with 1L trastuzumab-based regimens Supplemental Table 7: Demographics and clinical characteristics of the HER2+ mBC cohort treated with T-DXd Supplemental Table 8: Demographics and clinical characteristics of the HER2+ mBC cohort treated with T-DM1 Supplemental Table 9: Demographics and clinical characteristics of the HER2-low/ultra-low mBC cohort treated with 2L + T-DXd Supplemental Table 10: ERBB2 NGS and HER2 IHC/FISH concordance for 1,168 aGE patients Supplemental Table 11: Demographics and clinical characteristics of the HER2+ aGE cohort treated with 1L trastuzumab-based regimens.</p>